Back to results
US 8,802,098 B2Granted
Methods of promoting antitumor immunity by administering CD40 agonists and alpha-galactosyl ceramide
AssigneeImmurx, Inc.
InventorsCory Ahonen, Randolph Noelle
Life of this patent
Estimating the term…
Abstract
Adjuvant combinations comprising at least one NKT activator, such as alpha-galactosylceramide (α-Gal-Cer) or iGb3, a CD40 agonist and optionally an antigen are disclosed. The use of these immune adjuvants for treatment of various chronic diseases such as cancers is also provided.
Claims9
A method of promoting antitumor immunity in a subject in need thereof, consisting of the administration of a combination of adjuvants consisting of:
- (i) a human CD40 agonist, which is selected from an agonistic CD40 antibody or an agonistic CD40 antibody fragment or a multimeric CD40L polypeptide or multimeric CD40L protein fragment;
- (ii) alpha-galactosyl ceramide, and (iii) optionally a tumor antigen, wherein the administration of said combination elicits a synergistic enhancement of CD70 expression on an immune cell relative to either the CD40 agonist or the alpha galactosyl ceramide administered as a monotherapy.
Dependencies are inferred from the claim text.